Profound Medical Corp.
PROF · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Revenue | $5,230 | $2,211 | $2,621 | $5,327 |
| % Growth | 136.6% | -15.6% | -50.8% | – |
| Cost of Goods Sold | $1,343 | $593 | $768 | $1,698 |
| Gross Profit | $3,887 | $1,618 | $1,853 | $3,629 |
| % Margin | 74.3% | 73.2% | 70.7% | 68.1% |
| R&D Expenses | $5,358 | $6,098 | $4,808 | $6,736 |
| G&A Expenses | $0 | $0 | $0 | $11,819 |
| SG&A Expenses | $7,344 | $9,326 | $8,211 | $23,774 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $11,954 |
| Other Operating Expenses | $0 | $0 | $0 | $55,593 |
| Operating Expenses | $12,702 | $15,424 | $13,019 | $86,102 |
| Operating Income | -$8,814 | -$13,806 | -$11,166 | -$82,473 |
| % Margin | -168.5% | -624.4% | -426% | -1,548.3% |
| Other Income/Exp. Net | $1,045 | -$1,825 | $483 | $74,462 |
| Pre-Tax Income | -$7,769 | -$15,631 | -$10,683 | -$8,011 |
| Tax Expense | $120 | $64 | $41 | -$342 |
| Net Income | -$7,889 | -$15,695 | -$10,724 | -$7,669 |
| % Margin | -150.8% | -709.9% | -409.2% | -144% |
| EPS | 0.26 | -0.52 | -0.36 | -0.19 |
| % Growth | 150% | -44.4% | -89.5% | – |
| EPS Diluted | 0.26 | -0.52 | -0.36 | -0.19 |
| Weighted Avg Shares Out | 30,104 | 30,053 | 30,042 | 25,771 |
| Weighted Avg Shares Out Dil | 30,104 | 30,053 | 30,042 | 25,771 |
| Supplemental Information | – | – | – | – |
| Interest Income | $121 | $349 | $444 | -$1,638 |
| Interest Expense | – | $0 | $0 | $419 |
| Depreciation & Amortization | $145 | $141 | $163 | $538 |
| EBITDA | -$7,624 | -$13,665 | -$11,003 | -$12,055 |
| % Margin | -145.8% | -618% | -419.8% | -226.3% |